Jazz Pharmaceuticals PLC $JAZZ Stock Holdings Lessened by Amundi

Key Points

• Amundi has reduced its stake in Jazz Pharmaceuticals by 10.5%, now holding 72,068 shares worth approximately $8.7 million.
• Several hedge funds, including Nuveen LLC and Fuller & Thaler Asset Management, have significantly increased their positions in Jazz Pharmaceuticals during the same period.
• Jazz Pharmaceuticals' stock has a consensus rating of "Moderate Buy" with a target price averaging $178.67, as per recent analyst assessments.

Amundi lowered its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 10.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 72,068 shares of the specialty pharmaceutical company's stock after selling 8,413 shares during the quarter. Amundi owned 0.12% of Jazz Pharmaceuticals worth $8,707,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of JAZZ. Hurley Capital LLC acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at $25,000. Elequin Capital LP increased its position in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 183 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 119 shares in the last quarter. Picton Mahoney Asset Management increased its position in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after buying an additional 269 shares in the last quarter. Finally, Spire Wealth Management increased its position in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after buying an additional 161 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Royal Bank Of Canada raised their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Morgan Stanley lifted their price target on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a report on Thursday, August 28th. The Goldman Sachs Group lifted their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a report on Friday, August 29th. Finally, Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $178.67.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director directly owned 429,973 shares of the company's stock, valued at $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ:JAZZ traded down $2.30 during trading on Friday, reaching $126.16. 559,937 shares of the stock were exchanged, compared to its average volume of 682,018. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The firm has a market cap of $7.65 billion, a price-to-earnings ratio of -18.75, a price-to-earnings-growth ratio of 7.97 and a beta of 0.24. The firm's 50-day moving average price is $118.59 and its 200 day moving average price is $116.73.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm's revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.